Topline data results from the Phase 3 REACH trial of losmapimod for patients living with Facioscapulohumeral Muscular Dystrophy (FSHD) did not achieve its primary endpoint of change from baseline in reachable workspace.
Read the full press release here: ir.fulcrumtx.com/news-releases/…
Read the full press release here: ir.fulcrumtx.com/news-releases/…